Company Profile
Pfizer, Inc. Stock Price, News & Analysis
- Ticker:
- PFE
- Exchange:
- NYSE
- Sector:
- Biopharma, Oncology, Vaccines
- Location:
- United States
Stock performance
24.67 USD (+0.53%)
Close
Last updated: July 27, 2026
146B USD
Market cap
Why the stock is moving
As of Jul 27, 2026, PFE closed up 0.53% at $24.67. No new same-company headline was identified in the current news window.
Company overview
Business overview
Pfizer is a global pharmaceutical company spanning vaccines, oncology, inflammation, rare disease, and hospital products. The company’s narrative is now centered on post-COVID portfolio renewal and pipeline execution.
Geographic Base and Sector Classification
Headquartered in the United States and listed on NYSE, Pfizer has one of the broadest global commercial footprints in healthcare. It sits in large-cap pharma with strong international reach.
Business Model Characteristics
Pfizer depends on product sales, pipeline replacement, lifecycle management, and strategic capital allocation. Investors focus on earnings quality, launch timing, and how effectively the company can rebuild growth after major patent and demand transitions.
Position Within the Biotechnology Landscape
Pfizer is a mature large-cap pharma name with enough pipeline and vaccine exposure to retain catalyst sensitivity. It is not a binary biotech stock, but major approvals and portfolio shifts still matter.
Future catalysts
Pfizer’s near-term catalysts are likely to be post-Seagen oncology execution, selected late-stage pipeline updates, and evidence that the company’s post-COVID revenue mix is getting more stable. This matters because it helps show whether the company can turn its current footprint into a cleaner earnings profile. Better execution here can matter even before a new product or trial headline lands.
Recent news
The five most recent related feed items are shown below in reverse chronological order.
- 01
GSK to establish new flagship R&D centre on Cambridge Biomedical Campus, UK
GSK · Source: GSK plc
- 02
Legend Biotech to Host Investor Conference Call on Second Quarter 2026 Results
LEGN · Source: Legend Biotech Corporation
- 03
- 04
- 05
Kymera Therapeutics Appoints Terence Rooney, MD, as Chief Medical Officer
KYMR · Source: Kymera
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Pfizer, Inc. (PFE)?
Pfizer, Inc. (PFE) most recently closed at 24.67 USD, a +0.53% move versus the previous session.
What is the market cap of Pfizer, Inc. (PFE)?
Pfizer, Inc. currently has a market capitalization of 146B USD on BioPharmSignal.
What does Pfizer, Inc. do?
Pfizer is a global pharmaceutical company spanning vaccines, oncology, inflammation, rare disease, and hospital products. The company’s narrative is now centered on post-COVID portfolio renewal and pipeline execution.
On which exchange is PFE stock listed?
Pfizer, Inc. (PFE) is associated with NYSE, United States, Biopharma, Oncology, Vaccines.
What is Pfizer?
Pfizer’s near-term catalysts are likely to be post-Seagen oncology execution, selected late-stage pipeline updates, and evidence that the company’s post-COVID revenue mix is getting more stable.
Which conditions is Pfizer, Inc. targeting with Pfizer?
Pfizer, Inc. is associated with oncology, inflammatory disease, rare disease based on its company overview and current catalyst commentary.
How does Pfizer, Inc. describe recent progress with Pfizer?
Pfizer’s near-term catalysts are likely to be post-Seagen oncology execution, selected late-stage pipeline updates, and evidence that the company’s post-COVID revenue mix is getting more stable.
What is Seagen?
Pfizer’s near-term catalysts are likely to be post-Seagen oncology execution, selected late-stage pipeline updates, and evidence that the company’s post-COVID revenue mix is getting more stable.